

| Firm name and address                                                 |   |   |   | Drug labeler code                                                    |   |   |
|-----------------------------------------------------------------------|---|---|---|----------------------------------------------------------------------|---|---|
| *                                                                     | * | * | * | *                                                                    | * | * |
| Merial Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096-4640.. |   |   |   | 050604                                                               |   |   |
| *                                                                     | * | * | * | *                                                                    | * | * |
| (2) * * *                                                             |   |   |   |                                                                      |   |   |
| Drug labeler code                                                     |   |   |   | Firm name and address                                                |   |   |
| *                                                                     | * | * | * | *                                                                    | * | * |
| 050604                                                                |   |   |   | Merial Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096-4640. |   |   |
| *                                                                     | * | * | * | *                                                                    | * | * |

Dated: November 15, 2001.  
**Claire M. Lathers,**  
*Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.*  
[FR Doc. 01-30038 Filed 12-4-01; 8:45 am]  
**BILLING CODE 4160-01-S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Parts 510 and 524**

**Ophthalmic and Topical Dosage Form New Animal Drugs; Ivermectin Pour-On**

**AGENCY:** Food and Drug Administration, HHS.  
**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Virbac AH, Inc. The ANADA provides for topical use of ivermectin on cattle for treatment and control of various species of external and internal parasites.

**DATES:** This rule is effective December 5, 2001.

**FOR FURTHER INFORMATION CONTACT:** Lonnie W. Luther, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0209, e-mail: lluther@cvm.fda.gov.  
**SUPPLEMENTARY INFORMATION:** Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137, filed ANADA 200-

318 for VIRBAMEC (ivermectin) Pour-On. The ANADA provides for topical use of 0.5 percent ivermectin solution on cattle for the treatment and control of various species of gastrointestinal nematodes, lungworms, grubs, horn flies, lice, and mites. Virbac's VIRBAMEC Pour-On is approved as a generic copy of Merial Ltd.'s IVOMECEC Pour-On for Cattle, approved under NADA 140-841. The ANADA 200-318 is approved as of September 21, 2001, and the regulations in 21 CFR 524.1193 are amended to reflect the approval. The basis of approval is discussed in the freedom of information summary.  
In addition, Virbac AH, Inc., has not been previously listed in the animal drug regulations as a sponsor of an approved application. At this time, 21 CFR 510.600(c) is being amended to add entries for the firm.  
In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.  
The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.  
This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because

it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.  
**List of Subjects**  
*21 CFR Part 510*  
Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.  
*21 CFR Part 524*  
Animal drugs.  
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 524 are amended as follows:  
**PART 510—NEW ANIMAL DRUGS**  
1. The authority citation for 21 CFR part 510 continues to read as follows:  
**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.  
2. Section 510.600 is amended in the table in paragraph (c)(1) by alphabetically adding an entry for "Virbac AH, Inc." and in the table in paragraph (c)(2) by numerically adding an entry for "051311" to read as follows:  
**§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.**  
\* \* \* \* \*  
(c) \* \* \*  
(1) \* \* \*

| Firm name and address                                    |   |   |   | Drug labeler code                                        |   |   |
|----------------------------------------------------------|---|---|---|----------------------------------------------------------|---|---|
| *                                                        | * | * | * | *                                                        | * | * |
| Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137 |   |   |   | 051311                                                   |   |   |
| *                                                        | * | * | * | *                                                        | * | * |
| (2) * * *                                                |   |   |   |                                                          |   |   |
| Drug labeler code                                        |   |   |   | Firm name and address                                    |   |   |
| *                                                        | * | * | * | *                                                        | * | * |
| 051311                                                   |   |   |   | Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137 |   |   |
| *                                                        | * | * | * | *                                                        | * | * |

#### PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

3. The authority citation for 21 CFR part 524 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

##### § 524.1193 [Amended]

4. Section 524.1193 *Ivermectin pour-on* is amended in paragraph (b) by adding "051311," after "051259," and in paragraph (e)(2) by removing "Damalina" and by adding in its place "Damalinia".

Dated: November 9, 2001.

**Stephen F. Sundlof,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 01-30037 Filed 12-4-01; 8:45 am]

BILLING CODE 4160-01-S

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

##### Food and Drug Administration

##### 21 CFR Part 520

##### Oral Dosage Form New Animal Drugs; Carprofen

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Pfizer, Inc. The supplemental NADA provides for a once daily, 2-milligram per pound (mg/lb) dosage of carprofen, by oral caplet, for the relief of pain and inflammation associated with osteoarthritis in dogs.

**DATES:** This rule is effective December 5, 2001.

##### FOR FURTHER INFORMATION CONTACT:

Melanie R. Berson, Center for Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7540.

**SUPPLEMENTARY INFORMATION:** Pfizer, Inc., 235 East 42d St., New York, NY 10017-5755, filed a supplement to approved NADA 141-053 that provides for veterinary prescription use of RIMADYL (carprofen) Caplets for the relief of pain and inflammation associated with osteoarthritis in dogs. The supplemental NADA provides for a once daily, 2-mg/lb dosage for the oral caplet dosage form. The supplemental application is approved as of September 27, 2001, and the regulations are amended in 21 CFR 520.309 to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(iii)), this approval for non-food-producing animals qualifies for 3 years of marketing exclusivity beginning September 27, 2001, because the application contains substantial evidence of effectiveness of the drug involved or any studies of animal safety required for approval of the application and conducted or sponsored by the applicant.

The agency has determined under 21 CFR 25.33(d)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

##### List of Subjects in 21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

##### PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

2. Section 520.309 is amended in paragraph (a) by adding "(mg)" after "milligrams"; and by revising paragraph (d) to read as follows:

##### § 520.309 Carprofen.

\* \* \* \* \*

(d) *Conditions of use in dogs*—(1) *Amount*—(i) *Caplet*. 2 mg per pound (/lb) of body weight once daily or 1 mg/lb twice daily.

(ii) *Chewable tablet*. 1 mg/lb twice daily.

(2) *Indications for use*. For the relief of pain and inflammation associated with osteoarthritis in dogs.

(3) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.